Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Submitted by
admin
on December 6, 2014 - 11:18am
Source:
Yahoo/PR Newswire
News Tags:
Amgen
ONYX Pharmaceuticals
Kyprolis
Multiple Myeloma
Headline:
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Do Not Allow Advertisers to Use My Personal information
